MARKET

CALC

CALC

CALCIMEDICA INC
NASDAQ
0.6571
-0.0229
-3.37%
After Hours: 0.6437 -0.0134 -2.04% 19:04 05/15 EDT
OPEN
0.6831
PREV CLOSE
0.6800
HIGH
0.7238
LOW
0.6510
VOLUME
242.80K
TURNOVER
--
52 WEEK HIGH
7.20
52 WEEK LOW
0.4606
MARKET CAP
10.38M
P/E (TTM)
-0.5097
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: Meiragtx Holdings (MGTX), CalciMedica (CALC)
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: West Pharmaceutical Services (WST), CalciMedica (CALC) and Tyra Bioscience (TYRA)
TipRanks · 3d ago
CalciMedica returns to profit in Q1 FY26, posts $4.98 million net income
PUBT · 4d ago
CalciMedica GAAP EPS of -$0.30
Seeking Alpha · 4d ago
CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate
Benzinga · 4d ago
CalciMedica posts Q1 profit on higher other income, lower expenses
Reuters · 4d ago
*CalciMedica: Cash Position Sufficient to Fund Current Operating Plan Into 4Q >CALC
Dow Jones · 4d ago
CalciMedica Q1 FY26 results swing to net income of $5 million
PUBT · 4d ago
More
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Webull offers Calcimedica Inc stock information, including NASDAQ: CALC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CALC stock methods without spending real money on the virtual paper trading platform.